Context: The potential relationship between exosomal microRNAs (miRNAs) and clinical symptoms in breast cancer patients and the expression levels of exosomal miRNAs in patients undergoing surgery and chemotherapy are still unclear.
Aims: The aim of this study was to explore the correlation among exosomal miRNAs and clinical features and treatment in breast cancer patients.
Materials and Methods: First, exosomes were isolated from the serum of patients with breast cancer and healthy controls. Next, the features of exosomes were identified by transmission electron microscopy, nanoparticle tracking analysis, and Western blot assays. Then, we detected the expression of the top-ranked miRNAs (miR-3662, miR-16-1, miR-146a, miR-1290, and miR-29c) in sixty breast cancer patients and twenty healthy controls using quantitative real-time polymerase chain reaction.
Statistical Analysis Used: The differential expression was measured by the Mann–Whitney U-test.
Results: The relative expression of miR-3662, miR-146a, and miR-1290 in serum exosomes was significantly higher in patients than healthy controls. Moreover, significant differences were found in the lymph node metastasis and clinical stage of breast cancer as the miRNA levels changed, but their expression levels in exosomes and sera were not correlated. In addition, exosomal miR-3662, miR-146a, and miR-1290 were shown to be valuable biomarkers to monitor patient condition in the course of surgery and chemotherapy.
Conclusions: Exosomal miR-3662, miR-146a, and miR-1290 may have promising predictive value and could be utilized as biomarkers for diagnosis and preventative strategy development.


中文翻译：

---

miR-3662、miR-146a、miR-1290在乳腺癌患者血清外泌体中的检测意义


背景：外泌体微RNA（miRNA）与乳腺癌患者临床症状之间的潜在关系以及接受手术和化疗的患者外泌体miRNA的表达水平尚不清楚。
目的：本研究的目的是探讨外泌体 miRNA 与乳腺癌患者的临床特征和治疗之间的相关性。
材料和方法：首先，从乳腺癌患者和健康对照者的血清中分离外泌体。接下来，通过透射电子显微镜、纳米粒子追踪分析和蛋白质印迹分析鉴定外泌体的特征。然后，我们使用实时定量方法检测了 60 名乳腺癌患者和 20 名健康对照中排名靠前的 miRNA（miR-3662、miR-16-1、miR-146a、miR-1290 和 miR-29c）的表达。聚合酶链反应。
使用的统计分析：差异表达通过 Mann-Whitney U 检验测量。
结果：miR-3662、miR-146a和miR-1290在患者血清外泌体中的相对表达显着高于健康对照。此外，随着miRNA水平的变化，乳腺癌的淋巴结转移和临床分期存在显着差异，但它们在外泌体和血清中的表达水平没有相关性。此外，外泌体 miR-3662、miR-146a 和 miR-1290 被证明是监测手术和化疗过程中患者病情的重要生物标志物。
结论：外泌体 miR-3662、miR-146a 和 miR-1290 可能具有良好的预测价值，可用作诊断和预防策略制定的生物标志物。